TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample. Read More...
Select Product(s)

TruSight Tumor 170 Kit (24 Samples)



TruSight Tumor 170 Kit, With NextSeq v2.5 Reagents (24 Samples)



Product Highlights

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

  • Comprehensive Coverage of Cancer-Related Variants
    Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
  • Accurate Results from Low-Quality Samples1
    Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.

Fast, Automation-friendly Workflow
Prepare libraries for Illumina sequencing in less than a day. Illumina Qualified Methods are available on a range of automation platforms through our partners.

Frequently Purchased Together


Project Recommendations

Instrument Recommended Number of Samples Read Length
NextSeq 550 System Samples per run (high output): 16 (8 DNA + 8 RNA), 10 if DNA only, 16 if RNA only 2 × 101 bp (max recommended)

Case Studies

Accurate Identification of Cancer Biomarkers Paves the Way for Personalized Medicine

TruSight Tumor 170 Panel enables translational researchers to seek answers to multiple questions in one assay.

Read Interview
Almac Leverages TruSight Tumor 170

Learn how Almac uses TruSight Tumor 170 in clinical cancer research for pharmaceutical and biotech clients.

Read Article

Scientific Posters

AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples

Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.

Learn More

AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

Learn More

AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples

Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.

Learn More

Related Products

  1. Beta study. Data on file. March 2017.